Maqbul Jamil
Biography
M. Jamil is a commercial leader in the Pharmaceutical industry with two decades of strategic and operational experience in matrix organizations across geographies, Jamil has extensively worked with clinical development teams to commercialize breakthrough therapeutics, including the first small molecule targeted therapy and the first aPD-1 immunotherapy. Jamil is currently working at Merck & Co and is responsible for the commercialization of oncology pipeline assets. He is also an adjunct Professor at Columbia Business School in New York. Previously Jamil worked in marketing and commercial roles of increasing responsibility at Bayer, Eli Lilly and Novartis in US, Europe, Middle East and Emerging Markets to launch multiple products in numerous therapeutic areas. Jamil got his Ph.D. in Marketing from Kelley School of Business, Indiana University.
Teaching
Summer 2021
Biotech/Pharma Commercialization and Development Strategies
(EMBA)
Fall 2021
Biotech/Pharma Commercialization and Development Strategies
(MBA)
Spring 2020
Biotech/Pharmaceutical Commercialization & Business Development Strategies
(MBA)
Summer 2020
Biotech-Pharma Commercialization & Business Development Strategies
(EMBA)
Summer 2019
Pharmaceutical Commercialization - Strategy & Practice
(EMBA)
Fall 2019
Pharmaceutical Drug Commercialization: Strategy & Practice
(MBA)
Summer 2018
Pharmaceutical Commercialization - Strategy & Practice
(EMBA)
Fall 2018
Pharmaceutical Drug Commercialization: Strategy & Practice
(MBA)